Antiseptic-Antibiotic GUMBOS Overcome Bacterial Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The increasing resistance of Neisseria gonorrhoeae to current antibiotics, such as ceftriaxone and azithromycin, poses a significant threat, necessitating the development of new antibacterial agents that are resistant to inactivation by the bacteria.
Innovation Solution
The creation of GUMBOS (group of uniform materials based on organic salts) by combining antiseptics like chlorhexidine and octenidine with antibiotics like ceftriaxone, forming ion-pair solid-phase organic salts that synergistically enhance antibacterial activity and are less affected by beta-lactamases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotics (ceftriaxone, azithromycin) are used to treat gonorrhea, then treatment is effective against sensitive strains, but bacterial resistance develops leading to treatment failure
Solution Approach 1:
The patent combines an antibiotic (ceftriaxone) with an antiseptic (chlorhexidine or octenidine) to form a GUMBO complex. This merging of two different antimicrobial agents creates a synergistic effect where the antiseptic component protects the antibiotic from degradation by beta-lactamases while both agents work together to kill bacteria, overcoming resistance mechanisms that would normally inactivate the antibiotic alone.
Solution Approach 2:
The GUMBO (Group of Uniform Materials Based on Organic Salts) is a composite material formed by ionic association between an antibiotic and an antiseptic. This composite structure allows the two components to function together as a single therapeutic agent, with the antiseptic providing protection against enzymatic degradation and both components contributing to antibacterial activity, thereby overcoming bacterial resistance.
2Reliability
If antibiotic concentrations are increased to overcome resistance, then bacterial killing efficiency improves, but toxicity to host cells increases
Solution Approach 1:
The patent changes the chemical parameters of the antibiotic by forming it into a GUMBO complex with an antiseptic. This parameter change (forming an ionic association complex) fundamentally alters how the antibiotic interacts with bacterial targets and host cells. The complex achieves enhanced antibacterial efficacy at lower concentrations while the antiseptic component modulates the overall toxicity profile, reducing harm to host cells compared to using high concentrations of the antibiotic alone.
3Reliability
If beta-lactamase enzymes are produced by bacteria, then antibiotic structure is broken rendering it non-effective, but GUMBOS are less affected by these enzymes
Solution Approach 1:
The antiseptic component (chlorhexidine or octenidine) acts as an intermediary that protects the antibiotic (ceftriaxone) from degradation by beta-lactamase enzymes. The antiseptic forms an ionic association with the antibiotic, creating a complex where the antibiotic is less accessible to the enzyme or the antiseptic physically blocks enzymatic attack, thereby maintaining antibiotic stability and effectiveness in the presence of resistance mechanisms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
GUMBOS demonstrate enhanced efficacy against resistant strains of Neisseria gonorrhoeae and carbapenem-resistant Enterobacteriaceae, requiring lower concentrations to inhibit growth and showing reduced toxicity, potentially offering a viable alternative to current treatments.
Implementation Method 1
a composition comprising an antiseptic in ionic association with an antibiotic as an ion-pair solid-phase organic salt
Implementation Method 2
wherein the antiseptic and the antibiotic can synergistically interact whereby the composition has a Minimal Inhibitory Concentration (MIC) against a sensitive bacterial species that is less than the sum of the MICs of the antiseptic and the antibiotic individually
Data Source
AI summary
Ion-pairs known as GUMBOS (group of uniform materials based on organic salts) from antiseptics (chlorhexidine and octenidine) and the beta-lactam antibiotic, ceftriaxone. The antimicrobial efficacy of these GUMBOS and unreacted stoichiometric equivalent mixtures were compared to ceftriaxone and azithromycin alone. On a molar basis, GUMBOS were equivalent to ceftriaxone and 10× more effective in killing N. gonorrhoeae than azithromycin. They were more than 100× more effective than either antibiotic in killing CRE. A strategy involving the electrostatic interaction between a common antiseptic and a discontinued antibiotic (octenidine and carbenicillin) was also evaluated as a treatment for gonorrhoea. Octenidine/carbenicillin is a novel group of uniform materials based on organic salts (GUMBOS) with inherent in vitro antibacterial activity that comes from its parent antiseptic and antibacterial ions, octenidine and carbenicillin, respectively.